SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

Status Recruiting

Clinical Trial Summary

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.

Clinical Trial Description

Non-malignant central nervous system (CNS) tumor accounts for 70% of all primary CNS tumors, and over 300,000 patients were diagnosed with non-malignant CNS tumor per year in the United States. Not much is known about the natural history of non-malignant CNS tumors, as it is often treated immediately upon detection. However, some of them, especially small and asymptomatic non-malignant CNS tumors should not be treated immediately upon diagnosis but are observed and followed-up by repeated magnetic resonance imaging (MRI). This study aims to make a prospective cohort of non-malignant CNS tumors that do not require immediate treatment and to quantitatively analyze which factors are related to the growth of tumors. The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had MR re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. Non-malignant brain tumors are defined as radiologically diagnosed neoplasms of CNS WHO grade 2 or lower among primary intracranial tumors and include meningioma, schwannoma, pituitary adenoma, and glioma suspected to be non-malignant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05254197
Study type	Observational [Patient Registry]
Source	Seoul National University Hospital
Contact	Chul-Kee Park, MD PhD
Phone	+82220720347
Email	nsckpark@snu.ac.kr
Status	Recruiting
Phase
Start date	January 1, 2001
Completion date	December 31, 2035

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04081701` - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.	Phase 4
Recruiting	`NCT03631953` - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT04367779` - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn	`NCT00985036` - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients	N/A
Completed	`NCT01347307` - Stereotactic Body Radiotherapy for Spine Tumors	N/A
Completed	`NCT01811524` - The Etiology and Progression of Brain Tumors	N/A
Completed	`NCT03648034` - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality	N/A
Recruiting	`NCT06036706` - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:	N/A
Recruiting	`NCT06014905` - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma	Phase 1
Not yet recruiting	`NCT04386642` - Tranexamic Acid Reduce Blood Loss in Meningioma Resection	Phase 4
Active, not recruiting	`NCT04595786` - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection	N/A
Completed	`NCT04305470` - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma	Phase 3
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Not yet recruiting	`NCT02978677` - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas	N/A
Active, not recruiting	`NCT02933736` - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients	Early Phase 1
Completed	`NCT02267928` - Information Presentation Formats	N/A
Completed	`NCT00589784` - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Phase 2
Active, not recruiting	`NCT03071874` - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	Phase 2
Recruiting	`NCT05416567` - Embolization for Meningioma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON) — SOLOMON

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms